Literature DB >> 26260810

The future of targeted therapies for brain metastases.

Anna S Berghoff1,2, Matthias Preusser1,2.   

Abstract

Brain metastases (BM) are an increasing challenge in the management of patients with advanced cancer. Treatment options for BM are limited and mainly focus on the application of local therapies. Systemic therapies including targeted therapies are only poorly investigated, as patients with BM were frequently excluded from clinical trials. Several targeted therapies have shown promising activity in patients with BM. In the present review we discuss existing and emerging targeted therapies for the most frequent BM primary tumor types. We focus on challenges in the conduction of clinical trials on targeted therapies in BM patients such as patient selection, combination with radiotherapy, the obstacles of the blood-brain barrier and the definition of study end points.

Entities:  

Keywords:  ALK translocation; EGFR mutation; anti-HER2 therapy; brain metastases; targeted therapies

Mesh:

Substances:

Year:  2015        PMID: 26260810     DOI: 10.2217/fon.15.127

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  1 in total

1.  Predictors for a further local in-brain progression after re-craniotomy of locally recurrent cerebral metastases.

Authors:  Marcel A Kamp; Igor Fischer; Maxine Dibué-Adjei; Christopher Munoz-Bendix; Jan-Frederick Cornelius; Hans-Jakob Steiger; Philipp J Slotty; Bernd Turowski; Marion Rapp; Michael Sabel
Journal:  Neurosurg Rev       Date:  2017-12-20       Impact factor: 3.042

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.